BioCentury
BioCentury
ARTICLE | Finance

HotSpot heads for clinic with $65M series B round to develop allosteric modulators

With strategics, one crossover on board, HotSpot is likely to raise mezzanine round before exploring IPO

Paul Bonanos, Associate Editor
May 21, 2020 11:05 AM UTC


Access this Article
Request a Trial
Purchase This Article
Log in

BCIQ Company Profiles

HotSpot Therapeutics Inc.

BCIQ Target Profiles

Ribosomal protein S6 kinase 70kDa polypeptide 1 (S6K1) (RPS6KB1)

Protein kinase C (PKC) theta (PRKCQ)

BCIQ Company Profiles

HotSpot Therapeutics Inc.

BCIQ Target Profiles

Ribosomal protein S6 kinase 70kDa polypeptide 1 (S6K1) (RPS6KB1)

Protein kinase C (PKC) theta (PRKCQ)

About BioCentury

Privacy & Legal

Contact

About BioCentury

Company Overview
Management
Editorial & Research
Scientific Advisory Board

Privacy & Legal

User Agreement
Terms of Use
Privacy Policy
Cookie Policy
California Privacy Rights
Use of Images & Market Data
Reprints & Permissions

Contact

Contact Us
Advertising & Sponsorship
Customer Resource Center
Career Opportunities
Forgot Password
LinkedIn
Twitter
RSS
BioCentury
© 2022 BioCentury Inc. All Rights Reserved.
Copyright © 2022 BioCentury Inc. All Rights Reserved.
LinkedIn
Twitter
RSS